These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
Gluskin Sheff's David Rosenberg is painting a painful picture for stocks as earnings season goes into full gear.Futures Nowread more
Rossello is facing public furor over an obscenity-laced online chat that showed the governor and his close advisers insulting women and mocking constituents, including victims...Politicsread more
Imagine if instead of using drugs or surgery, a doctor could simply insert a gene into a patient's cell to treat or prevent disease.
Gene therapy is endeavoring to do just that and could emerge in the coming years as a viable alternative for treatment. Certain conditions that previously couldn't be treated, such as forms of blindness, types of cancer or more rare conditions like sickle cell disease are now being researched with this alternative treatment.
Phil Nadeau, biotechnology analyst with Cowen and Company, predicts there will be several gene therapy products approved by the F.D.A. within the next few years. He told CNBC recently he sees more than $1 billion in gene therapy sales worldwide, which ultimately means significant investments in gene therapy in the near future.
"In the past, most major companies stayed away from having gene therapy programs. In the future, we think, it's going to be a standard treatment," he said.
Safety challenges have historically been the largest barrier for gene therapy, Nadeau explained. For example, insuring that the insertion of new genes doesn't cause cancer or prompt other reactions have been on researcher's minds, but he's confident that more studies are easing concerns.
"Spark Therapeutics is likely to have the first gene therapy program approved in the U.S. It's a recent IPO, but we think it's a really promising company."